INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

A Comprehensive Review on Noro Virus

Mercy Amulya*

K. V. Subba Reddy Institute of Pharmacy, Kurnool.

ARTICLE INFO

Published: 07 Aug 2025
Keywords:
rapid transmission, low infectious dose, and environmental stability, norovirus remains
DOI:
10.5281/zenodo.16758790

ABSTRACT

Norovirus is a highly contagious, non-enveloped RNA virus that is recognized as the leading cause of acute gastroenteritis across all age groups globally. It belongs to the Caliciviridae family and is transmitted primarily through the fecal-oral route, contaminated food and water, direct person-to-person contact, and contact with contaminated surfaces. Norovirus infections can occur year-round but are more prevalent during the winter months, often leading to outbreaks in closed and semi-closed communities such as hospitals, schools, cruise ships, and nursing homes. Clinically, norovirus infection is characterized by a sudden onset of nausea, vomiting, watery diarrhea, abdominal cramps, and sometimes low-grade fever, with symptoms typically lasting 1 to 3 days. While most cases are self-limiting, severe dehydration and complications can occur, especially in young children, the elderly, and immunocompromised individuals. The virus exhibits high genetic diversity, with genogroup II, particularly GII.4 variants, being the most prevalent in human infections. This diversity, along with short-lived immunity following infection, contributes to frequent reinfections and challenges in vaccine development. Diagnosis is primarily made using reverse transcription polymerase chain reaction (RT-PCR) testing of stool samples. Currently, there is no specific antiviral treatment or licensed vaccine for norovirus; management is supportive, focusing on hydration and symptomatic relief. Preventive strategies rely on strict hygiene practices, including handwashing, disinfection of surfaces, and proper food handling. Given its rapid transmission, low infectious dose, and environmental stability, norovirus remains a significant public health burden worldwide, causing hundreds of millions of cases and thousands of deaths annually. Ongoing research efforts are aimed at understanding its pathogenesis, improving diagnostic tools, and developing effective vaccines to reduce the global impact of norovirus-associated disease.

INTRODUCTION

Norovirus, often called the "winter vomiting bug," is a major cause of viral gastroenteritis worldwide.

***Corresponding Author:** Mercy Amulya
Address: *K. V. Subba Reddy Institute of Pharmacy, Kurnool.*
Email ✉: mpmamulya9@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

It belongs to the Caliciviridae family, named after the Latin word for "cup," due to the cup-like indentations seen on the virus's surface under an electron microscope.

This family also includes other viruses like:

- Lago virus, which affects rabbits and hares,
- Vesivirus, known to infect animals such as cats and sea lions, and
- Sapo virus, another virus that can infect humans.

Noroviruses are tiny, round viruses—just 27 to 30 nanometers in diameter. Their outer shell, or capsid, is made of 180 copies of a protein called VP1 arranged in a symmetrical icosahedral shape. A smaller protein, VP2, may help stabilize the structure. The inner part of VP1 (called the S domain) forms the main shell, while the outer part (P domain) sticks out and helps the virus attach to human cells by binding to molecules called histo-blood group antigens (HBGAs). This area also plays a role in how our immune system recognizes the virus. The norovirus genome is made up of about 7,500 RNA building blocks and is organized into three sections called open reading frames (ORFs):

- ORF1 codes for a large polyprotein, which is cut into smaller proteins by the virus itself. These include enzymes like the viral protease and RNA polymerase, which are essential for virus replication.
- ORF2 encodes the VP1 protein (the main capsid component).
- ORF3 encodes VP2 (the minor capsid protein).

The most variable region of the genome is a section of VP1 called the P2 subdomain. This variability allows norovirus to evolve rapidly, which is one reason why people can get infected multiple times. On the other hand, certain regions—like the junction between ORF1 and ORF2—are highly conserved, meaning they don't change much over time. These areas are critical for viral replication. Noroviruses are genetically diverse. Based on the VP1 sequence, they are grouped into five major genogroups (GI to GV), with over 29 distinct clusters. Genogroups I and II are the most common in humans. Genogroup III infects cattle, genogroup IV infects both humans and dogs, and genogroup V is found in mice. Norovirus is one of the leading causes of acute gastroenteritis (AGE) around the world—a condition marked by sudden-onset vomiting and diarrhea. It affects people of all ages but is especially dangerous for young children, older adults, and those with weakened immune systems. Every year, this highly contagious virus causes significant illness and even death, regardless of a country's income level. One of the biggest challenges in preventing norovirus is its genetic diversity. There are many different strains, and several of them circulate at the same time. Among these, the GII.4 variant is the most common, though others like GII.2, GII.3, and GII.6 have also been widespread in recent years. Norovirus spreads easily, mainly through the fecal-oral route—meaning it can be passed from contaminated food, water, surfaces, or even person-to-person contact. It only takes a tiny amount of the virus to make someone sick. This makes controlling outbreaks very difficult, especially in places like nursing homes, hospitals, and daycare centers, where people live or work in close contact. Outbreaks in these settings often spread rapidly and cause significant disruption and healthcare costs. For those most vulnerable—infants, the elderly, and immunocompromised individuals—norovirus infections can become severe. Unfortunately, there's no specific antiviral

treatment. Care mostly focuses on staying hydrated and relieving symptoms. As of now, there's no approved vaccine for norovirus, though several are currently being tested and developed.

Epidemiology

Norovirus is one of the most common causes of acute gastroenteritis worldwide, responsible for hundreds of millions of cases each year across all age groups. It spreads quickly and efficiently, especially in places where people are in close contact, such as schools, hospitals, cruise ships, and nursing homes. Transmission occurs primarily through contaminated food or water, direct person-to-person contact, or touching contaminated surfaces. The virus is highly contagious; just a few viral particles can cause infection, and individuals remain infectious even after symptoms subside. Outbreaks often spike during colder months, earning norovirus the nickname "winter vomiting bug." While people of all ages can be affected, young children, the elderly, and immunocompromised individuals are most vulnerable to severe illness, hospitalizations, and, in rare cases, death. Despite its high global burden, norovirus often flies under the public radar. Its symptoms—vomiting, diarrhea, stomach cramps—can feel like a short-lived stomach flu, but the virus's true impact is far more serious. Globally, it causes an estimated 685 million cases and over 200,000 deaths annually, with the greatest toll in low-income countries. There is currently no specific antiviral treatment or licensed vaccine for norovirus, making prevention a challenge. Simple but crucial measures like hand hygiene, safe food practices, and isolating symptomatic individuals remain our best defense. Humanizing this issue means recognizing that behind every case is a child missing school, an elderly person at risk of complications, or a caregiver struggling to manage an outbreak at home. Improving global sanitation, increasing awareness, and investing in vaccine development are essential steps to reduce the burden of this often-overlooked but deeply disruptive virus.

Etiology

Norovirus is an RNA virus that belongs to the Caliciviridae family and is a leading cause of acute gastroenteritis worldwide. Its etiology is primarily rooted in its high infectivity and environmental stability. The virus has a low infectious dose — as few as 18 viral particles can cause infection — and is transmitted mainly via the fecal-oral route. Contaminated food or water, direct person-to-person contact, and contact with contaminated surfaces are common transmission pathways. Norovirus is particularly notorious in closed or crowded settings such as schools, hospitals, nursing homes, cruise ships, and military barracks, where it can spread rapidly. The virus is shed in large quantities in stool and vomitus, and shedding can continue even after symptoms resolve, making containment difficult. Genetically, noroviruses are highly diverse, with multiple genogroups and genotypes, but the most clinically significant is genogroup II, genotype 4 (GII.4), which is responsible for the majority of outbreaks globally. Frequent mutations and recombination events allow the virus to evade host immunity, leading to repeated infections across a lifetime. Immunity following infection is often short-lived and incomplete, which further complicates prevention efforts. Environmental resilience also plays a role in its persistence — norovirus can survive on surfaces for weeks and is resistant to many common disinfectants. These combined factors — low infectious dose, genetic variability, prolonged shedding, and environmental stability — make norovirus a formidable pathogen and a consistent cause of outbreaks and endemic disease.

Pathophysiology

Ingestion of Norovirus

↓

Virus survives stomach acid

↓

Virus reaches small intestine

↓

Infection of enterocytes (intestinal epithelial cells)

↓

Disruption of intestinal epithelial barrier

↓

Malabsorption and enzyme dysfunction

↓

Secretory diarrhea and fluid loss

↓

Activation of immune response

- Cytokine release

- Inflammation

↓

Clinical symptoms appear

- Nausea

- Vomiting

- Diarrhea

- Abdominal cramps

↓

Viral shedding in faces and vomitus

↓

Continued transmission (even after symptoms resolve)

Norovirus pathophysiology begins with ingestion of the virus through contaminated food, water, or contact with infected individuals or surfaces. Once ingested, norovirus resists degradation by stomach acid due to its non-enveloped, sturdy capsid. It then travels to the small intestine, where it primarily targets and infects the epithelial cells lining the intestinal mucosa, particularly enterocytes. Unlike some viruses, norovirus does not cause significant structural damage to the intestinal lining; instead, it disrupts cellular functions and affects the brush border enzymes, impairing nutrient absorption. The infection leads to alterations in gastric motility and electrolyte transport, resulting in malabsorption, secretory diarrhea, and osmotic imbalance. Additionally, norovirus infection triggers an innate immune response, leading to inflammation and cytokine release, which further contributes to gastrointestinal symptoms like nausea, vomiting, abdominal cramps, and diarrhea. The symptoms usually begin 12 to 48 hours after exposure and last 1 to 3 days. Despite the self-limiting nature in most individuals, the virus is shed in large amounts in feces and vomitus, even after recovery, contributing to ongoing transmission. Immunity is typically short-lived and strain-specific, meaning reinfection with different genotypes is common throughout life.

Signs And Symptoms

Norovirus infection, often called the "stomach flu" (though unrelated to influenza), typically presents suddenly and includes a range of gastrointestinal symptoms. The symptoms usually begin 12 to 48

hours after exposure and can last for 1 to 3 days. While most people recover without complications, symptoms can be more severe in young children, older adults, and immunocompromised individuals.

Common Signs and Symptoms:

1. Nausea
2. Vomiting – sudden and forceful, more common in children
3. Watery diarrhea – frequent and non-bloody
4. Abdominal cramps or pain
5. Low-grade fever
6. Headache
7. Muscle aches
8. Malaise or fatigue

Other Possible Symptoms:

1. Chills
2. Sweating
3. Dehydration (due to fluid loss from vomiting and diarrhea), which can lead to:
4. Dry mouth and throat
5. Dizziness or light-headedness
6. Reduced urination
7. Sunken eyes in children

Clinical Features

- Sudden onset of vomiting – often the first and most prominent symptom.
- Watery, non-bloody diarrhea – typically lasts 1–3 days.
- Nausea – commonly accompanies vomiting.
- Abdominal cramps – due to gastrointestinal inflammation.
- Low-grade fever – usually mild, but present in some cases.
- Headache – due to dehydration or systemic reaction.
- Myalgia (muscle aches) – general body discomfort is common.
- Chills – may accompany fever in some individuals.
- Fatigue – post-illness tiredness or weakness is typical.
- Malaise – a general feeling of being unwell.
- Dehydration – especially in children and elderly due to fluid loss.
- Dry mouth and mucous membranes – due to fluid depletion.
- Decreased urine output – a sign of significant dehydration.
- Dizziness or lightheadedness – from fluid and electrolyte imbalance.
- Weight loss – due to reduced intake and fluid loss.
- Loss of appetite – anorexia may persist for several days.
- Irritability or lethargy in children – a warning sign of dehydration.
- Increased thirst – a compensatory response to fluid loss.
- Symptom onset within 12–48 hours of exposure – short incubation period.
- Self-limiting illness lasting 1–3 days – most cases resolve without treatment.

Diagnosis

The diagnosis of norovirus infection is primarily clinical, based on the patient's symptoms and recent history of exposure, especially during outbreaks. Patients typically present with acute onset of nausea, vomiting, watery non-bloody diarrhea, and abdominal cramps, often accompanied by low-grade fever, headache, and myalgia. The illness is self-limiting, usually resolving within 24 to 72 hours. Laboratory confirmation, although not always necessary, can be achieved through reverse transcription-polymerase chain reaction (RT-PCR), which is the gold standard for detecting norovirus RNA in stool specimens. Enzyme immunoassays (EIAs) are also available for antigen detection but are less sensitive than molecular methods. Diagnosis is especially important in vulnerable populations such as the elderly, infants, or immunocompromised individuals, where complications such as dehydration may arise. Public health surveillance and outbreak investigations often rely on laboratory confirmation in a subset of cases. Clinical differentiation from other causes of gastroenteritis is challenging due to overlapping symptoms, but the rapid onset and short duration of illness, coupled with history of contact or community outbreak, are suggestive of norovirus. Routine stool cultures are generally negative since bacterial pathogens are absent, emphasizing the role of viral testing in appropriate settings.

Laboratory Test

1. Reverse Transcription Polymerase Chain Reaction (RT-PCR)

- Gold standard test for detecting norovirus RNA.
- Highly sensitive and specific.
- Detects the virus in stool, vomitus, or environmental samples.
- Can identify genogroups and genotypes (e.g., GI, GII).

2. Enzyme Immunoassays (EIAs)

- Detect norovirus antigens in stool samples.
- Less sensitive than RT-PCR, especially for low viral loads.
- Useful for outbreak investigations and screening in resource-limited settings.

3. Immunochromatographic Assays (Rapid Tests)

- Quick, point-of-care detection of norovirus antigens.
- Moderate sensitivity; mainly used during outbreaks or in hospitals.
- Suitable for preliminary testing, not confirmatory.

4. Electron Microscopy (EM)

- Visualizes virus particles in stool.
- Requires a high viral load and skilled personnel.
- Rarely used now due to lower sensitivity and availability of better methods.

5. Viral Genotyping

- Performed after PCR to determine the specific norovirus strain (e.g., GII.4).
- Helps in epidemiological surveillance and understanding transmission patterns.

Sample Requirements:

- Stool specimens are preferred (5–10 mL or g), ideally collected within 48–72 hours of symptom onset.
- Samples should be stored at 4°C for short-term or -70°C for long-term preservation.

Treatment

Norovirus infection is typically self-limiting, and treatment is primarily supportive, aimed at relieving symptoms and preventing dehydration. There are no specific antiviral drugs approved for norovirus; thus, oral rehydration therapy (ORT) remains the cornerstone of management, especially in children and the elderly. ORT helps replace lost fluids and electrolytes, mitigating the risk of hypovolemia and electrolyte imbalances. In severe cases, particularly in vulnerable populations, intravenous fluid administration may be necessary. Antiemetic agents like ondansetron can help reduce vomiting and improve fluid intake. Antibiotics are ineffective, as norovirus is viral, and antidiarrheal medications are generally not recommended in children due to potential complications. Probiotics have shown limited benefit in reducing the duration of diarrhea in some cases but are not a standard treatment. Emphasis is also placed on infection control measures to limit spread, including proper hand hygiene, disinfection of contaminated surfaces, and isolation during the infectious period. Although vaccine development is underway, no norovirus vaccine is currently available for public use. The prognosis is generally good, with symptoms resolving in 1–3 days for most individuals. However, immunocompromised patients may experience prolonged or severe illness and require close monitoring.

Prevention

Preventing norovirus infection requires a combination of personal hygiene, environmental sanitation, and safe food practices. Hand hygiene is the most effective measure—hands should be washed thoroughly with soap and water for at least 20 seconds, especially after using the toilet, changing diapers, or before preparing and eating food, as alcohol-based hand sanitizers are less effective against norovirus. Safe food handling is also crucial; fruits and vegetables should be washed thoroughly, and shellfish must be cooked completely since undercooked seafood is a common transmission source. People experiencing vomiting or diarrhea should avoid preparing food or caring for vulnerable populations (e.g., infants, the elderly) until at least 48 hours after symptoms subside. In settings like homes, schools, and healthcare facilities, surfaces contaminated by vomit or stool should be disinfected with chlorine bleach solutions (1000–5000 ppm) to kill the virus. Contaminated clothing or linens should be immediately removed and washed using hot water and detergent. In outbreak-prone areas, isolating infected individuals can help limit spread. Public health education and awareness campaigns in food service, healthcare, and community environments are essential to reinforce these measures. While no vaccine is currently available for public use, vaccine development is ongoing and may become a future preventive tool. Norovirus is highly contagious and resilient, making proactive hygiene and infection control vital to prevent widespread outbreaks.

CONCLUSION

Norovirus remains a leading cause of acute gastroenteritis worldwide, affecting people of all ages and posing significant health and economic burdens, especially in communal settings such as schools, healthcare facilities, and cruise ships. Despite being self-limiting in most cases, the virus's high infectivity, environmental persistence, and resistance to common disinfectants make controlling its spread particularly challenging. Effective prevention hinges on strict hygiene practices, safe food handling, environmental sanitation, and public health awareness. Although no specific antiviral treatment or licensed vaccine exists currently,

ongoing research offers hope for future preventive options. Timely diagnosis, supportive care, and infection control are key to managing outbreaks and reducing morbidity, especially in vulnerable populations such as young children, the elderly, and immunocompromised individuals. With comprehensive hygiene education and coordinated public health strategies, the global impact of norovirus can be significantly reduced.

REFERENCES

1. Patel MM, Hall AJ, Vinjé J, Parashar UD. Noroviruses: a comprehensive review. J Clin Virol. 2009 Jan;44(1):1–8.
2. Hall AJ, Lopman BA, Payne DC, Patel MM, Gastanaduy PA, Vinjé J, Parashar UD. Norovirus disease in the United States. Emerg Infect Dis. 2013 Aug;19(8):1198–205.
3. Vega E, Barclay L, Gregoricus N, Shirley SH, Lee D, Vinjé J. Genotypic and epidemiologic trends of norovirus outbreaks in the United States, 2009 to 2013. J Clin Microbiol. 2014 Feb;52(1):147–55.
4. Vinjé J. Advances in laboratory methods for detection and typing of norovirus. J Clin Microbiol. 2015 Feb;53(2):373–81.
5. Ahmed SM, Hall AJ, Robinson AE, Verhoef L, Premkumar P, Parashar UD, Koopmans M, Lopman BA. Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysis. Lancet Infect Dis. 2014 Aug;14(8):725–30.
6. Hall AJ, Vinjé J, Lopman B, Park GW, Yen C, Gregoricus N, Parashar UD. Updated norovirus outbreak management and disease prevention guidelines. MMWR Recomm Rep. 2011 Mar;60(RR-3):1–18.
7. Atmar RL, Estes MK. The epidemiologic and clinical importance of norovirus infection. Gastroenterol Clin North Am. 2006 Sep;35(2):275–90.
8. Cannon JL, Barclay L, Collins NR, Wikswo ME, Castro CJ, Magana LC, Gregoricus N, Marine RL, Chhabra P, Vinjé J. Genetic and epidemiologic trends of norovirus outbreaks in the United States from 2013 to 2016. J Clin Microbiol. 2017 Jul;55(7):2208–21
9. Green KY. Caliciviridae: the noroviruses. In: Knipe DM, Howley PM, editors. Fields Virology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 582–608.
10. Robilotti E, Deresinski S, Pinsky BA. Norovirus. Clin Microbiol Rev. 2015 Apr;28(1):134–64.
11. Teunis PF, Moe CL, Liu P, Miller SE, Lindesmith L, Baric RS, Le Pendu J, Calderon RL. Norwalk virus: how infectious is it? J Med Virol. 2008 Aug;80(8):1468–76.
12. Yen C, Wikswo ME, Lopman BA, Vinjé J, Parashar UD, Hall AJ. Impact of norovirus-associated diarrhea: epidemiologic and economic burden in the United States. Expert Rev Anti Infect Ther. 2011 Mar;9(3):467–77.
13. Lee RM, Lessler J, Lee RA, Rudolph KE, Reich NG, Perl TM, Cummings DA. Incubation periods of viral gastroenteritis: a systematic review. BMC Infect Dis. 2013 May;13:446.
14. Parra GI, Green KY. Genome of emerging norovirus GII.17, United States, 2014. Emerg Infect Dis. 2015 Aug;21(8):1477–9.
15. Karst SM. Pathogenesis of noroviruses, emerging RNA viruses. Viruses. 2010 Mar;2(3):748–81.
16. Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, Estes MK. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med. 2011 Dec;365(23):2178–87.
17. Bok K, Green KY. Norovirus gastroenteritis in immunocompromised patients. N Engl J Med. 2012 Feb;367(22):2126–32.

18. Verhoef L, Hewitt J, Barclay L, Ahmed SM, Lake R, Hall AJ, Lopman B, Kroneman A, Vennema H, Vinjé J, Koopmans M. Norovirus genotype profiles associated with foodborne transmission, 1999–2012. Emerg Infect Dis. 2015 Mar;21(4):592–9.
19. Kirby A, Gurgel RQ, Dove W, Vieira SC, Cunliffe NA, Cuevas LE. An evaluation of commercial and in-house diagnostic assays for detecting norovirus in faecal samples. J Med Virol. 2010 Oct;82(10):1614–9.
20. Pringle K, Lopman B, Vega E, Vinjé J, Parashar UD, Hall AJ. Noroviruses: epidemiology, immunity and prospects for prevention. Future Microbiol. 2015 Apr;10(1):53–67.
21. Let me know if you want them formatted into a reference list section for your Word document, or if you need in-text citations matched as well.

HOW TO CITE: Mercy Amulya*, A Comprehensive Review on Noro Virus, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 8, 714-722. https://doi.org/10.5281/zenodo.16758790